

Stelara - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.				
Member Name:	Prescriber Name:			
Member Number:	Fax: Phone:			
Date of Birth:	Office Contact:			
Line of Business: Medicare Advantage	NPI: State Lic ID:			
Address:	Address:			
City, State ZIP:	City, State ZIP:			
Primary Phone:	Specialty/facility name (if applicable):			
REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below he life or health of the enrollee or the enrollee's ability to regain maximum for the enrollee or the enrollee's ability to regain maximum for the enrollee.	ow, I certify that applying the 72 hour standard review timeframe may seriously jeopardize unction.			
Drug Name:				
Strength:				
Directions / SIG:				
Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.				
Q1. Is this a request for continuation?				
☐ Yes - Go to 2	☐ No - Go to 3			
Q2. Is there documentation of improvement in symptoms?				
□Yes	□ No			
Q3. Is Stelara being prescribed by or in consultation with a dermatologist, rheumatologist, or gastroenterologist?				
☐ Yes	□ No			
Q4. Is there documentation of tuberculosis (TB) testing that is negative for latent tuberculosis infection OR positive for latent tuberculosis with documentation that treatment is completed or is receiving treatment for latent tuberculosis?				
☐ Yes	□ No			
Q5. Is the patient being treated with live vacci	ines?			
□Yes	□No			

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



Stelara - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Member Name:	Prescriber Name:	
Q6. Does the patient have an active, serious infection?		
□Yes	□ No	
Q7. Does the patient have a confirmed diagnosis of moderate to severe plaque psoriasis and is a candidate for phototherapy or systemic therapy? If No, go to 12.		
☐ Yes	□ No	
Q8. Is the patient 6 to 17 years of age?		
☐ Yes	□No	
Q9. Is there documentation of an inadequate response, intolerance, or contraindication to Enbrel?		
□Yes	□No	
Q10. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q11. Is there documentation of an inadequate response, intolerance, or contraindication to two of the following: Enbrel, an adalimumab containing product, Skyrizi, Otezla?		
☐Yes	□No	
Q12. Does the patient have a confirmed diagnosis of active psoriatic arthritis? If No, go to 15.		
☐ Yes	□ No	
Q13. Is the patient 6 to 17 years of age?		
☐ Yes	□ No	
Q14. Is there documentation of an inadequate response, intolerance, or contraindication to Enbrel?		



Stelara - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Member Name:	Prescriber Name:	
□Yes	□ No	
Q15. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q16. Is there documentation of an inadequate response, intolerance, or contraindication to two of the following: Enbrel, an adalimumab containing product, Skyrizi, Otezla, Xeljanz, Xeljanz XR?		
☐ Yes	□ No	
Q17. Does the patient have a confirmed diagnosis of moderately to severely active Crohn's disease? If No, go to 18.		
☐ Yes	□ No	
Q18. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q19. Is there documentation of an inadequate response, intolerance, or contraindication to an adalimumab containing product and Skyrizi?		
□Yes	□ No	
Q20. Does the patient have a confirmed diagnosis of moderately to severely active Ulcerative Colitis?		
☐ Yes	□ No	
Q21. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q22. Is there documentation of an inadequate response, intolerance, or contraindication to an adalimumab containing product and Xeljanz or Xeljanz XR?		
☐ Yes	□ No	



Stelara - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Member Name:	Prescriber Name:	
Q23. Additional Information:		
Q24. Requested Duration:		
☐ 12 months	☐ Other	
Prescriber Signature		Date
		v2025

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document